Trifluoroacetic acid → HCID 131732819, compound
Reaction equation
COC1C=CC(C[NH:8][C:9]([NH:11][C:12]2[N:17]=[CH:16][C:15]3[C:18]([C:40]4[CH:45]=[CH:44][N:43]=[C:42]([CH3:46])[CH:41]=4)=[N:19][N:20](C(C4C=CC=CC=4)(C4C=CC=CC=4)C4C=CC=CC=4)[C:14]=3[CH:13]=2)=[O:10])=CC=1.[C:49]([OH:55])([C:51]([F:54])([F:53])[F:52])=[O:50]>O1CCOCC1>[OH:55][C:49]([C:51]([F:54])([F:53])[F:52])=[O:50].[CH3:46][C:42]1[CH:41]=[C:40]([C:18]2[C:15]3[CH:16]=[N:17][C:12]([NH:11][C:9]([NH2:8])=[O:10])=[CH:13][C:14]=3[NH:20][N:19]=2)[CH:45]=[CH:44][N:43]=1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
A crude mixture of 1-(4-methoxybenzyl)-3-(3-(2-methylpyridin-4-yl)-1-trityl-1H-pyrazolo[4,3-c]pyridin-6-yl)urea prepared according to Scheme 6 (35 mg, 0.055 mmol) in 1,4-dioxane (0.25 mL) was treated at room temperature with TFA (0.25 mL) and the reaction mixture stirred for 5 h, then additional TFA (0.25 mL) was added and the reaction mixture stirred for 16 h at room temperature and then concentrated in vacuo. The residue was purified by MS-directed reverse phase preparative-HPLC (C-18 stationary phase, eluting with a H2O/MeCN gradient with 0.1% TFA), to give 1-(3-(2-methylpyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)urea TFA salt as a yellow solid (4 mg, 0.01 mmol, 19%). MS ESI calc'd. for C13H13N6O [M+H]+ 269, found 269. 1H NMR (600 MHz, DMSO-d6) δ 13.82 (br s, 1H), 9.31 (s, 1H), 9.19 (s, 1H), 8.70 (s, 1H), 8.30-8.15 (m, 2H), 7.88 (s, 1H), 2.70 (s, 3H).
Workup
- customprepared
- stirringthe reaction mixture stirred for 16 h at room temperature
- concentrationconcentrated in vacuo
- customThe residue was purified by MS-directed reverse phase preparative-HPLC (C-18 stationary phase
- washeluting with a H2O/MeCN gradient with 0.1% TFA),
Sources & evidence
- ORD record
- ord-6c0d483f6b05498bbc14a83fdb94b8ee
- Source dataset
- uspto-grants-2015_05
- Patent number
- US09023865B2
Reaction notes
Loading…